BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 106,193 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 12.8% during the third quarter, HoldingsChannel reports. The firm owned 724,182 shares of the biopharmaceutical company’s stock after selling 106,193 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Ultragenyx Pharmaceutical were worth $40,228,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Ultragenyx Pharmaceutical by 3.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock worth $166,632,000 after purchasing an additional 120,175 shares during the last quarter. Vanguard Group Inc. increased its holdings in Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 8,700,007 shares of the biopharmaceutical company’s stock worth $406,203,000 after purchasing an additional 26,575 shares during the period. Frazier Life Sciences Management L.P. purchased a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth $17,468,000. Teachers Retirement System of The State of Kentucky bought a new stake in Ultragenyx Pharmaceutical during the 1st quarter valued at $691,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Ultragenyx Pharmaceutical in the 1st quarter worth $714,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Trading Down 0.8 %

NASDAQ RARE opened at $46.02 on Friday. Ultragenyx Pharmaceutical Inc. has a 12-month low of $37.02 and a 12-month high of $60.37. The company has a fifty day simple moving average of $53.60 and a two-hundred day simple moving average of $48.38. The stock has a market cap of $4.25 billion, a P/E ratio of -7.11 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. During the same quarter last year, the business posted ($2.23) EPS. The firm’s quarterly revenue was up 42.3% on a year-over-year basis. As a group, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.21 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. This represents a 0.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. The trade was a 7.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,556 shares of company stock worth $1,515,967 over the last three months. 5.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on RARE. Wells Fargo & Company lifted their price objective on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Wedbush increased their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, TD Cowen increased their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.46.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.